Feb 19, 2021

AMIZON® was upgraded again

The new properties of the medicinal product have been discovered during another stage of AMIZON® mechanism of action and efficacy studies in the USA, Germany, Austria and the United Kingdom. This makes it possible to differently consider AMIZON® mechanism of action and efficacy against a number of respiratory viruses, including influenza A and B.

The new properties of Amizon have been discovered following the studies conducted in other countries with strict regulation. The changes have been made in the instruction for medical use and approved by Order of Ministry of Health of Ukraine No. 90dated 20/01/2021.

The use of Amizon in the treatment of influenza and acute respiratory viral infections (ARVI) reduces:

What has changed?

Mechanism of action.

Such typical symptomatic effects as antipyretic, anti-inflammatory, analgesic have been deleted from the instruction for medical use. This means that AMIZON® is a direct-acting antiviral medicinal product, i.e. it affects the disease cause rather than just relieves its symptoms.

The studies have shown that the antiviral action of enisamium iodide (the active substance of Amizon) is associated with the inhibition of influenza virus RNA polymerase. In other words, Amizon reduces the growth of viruses and facilitates to recover from flu.


AMIZON® has demonstrated efficacy against influenza A and B virus strains. Therefore, AMIZON® is indicated for the treatment and prevention of influenza and ARVI.

The active substance of AMIZON® has been proven to have antiviral action against various influenza A virus (H1N1, H3N2, H5N1, H7N9), influenza B virus, respiratory syncytial virus and coronavirus strains (NL-63). In addition, enisamium iodide has been shown its effect against influenza A and B virus strains in in vitro studies.


AMIZON® can be used both for the treatment and for the prevention of influenza and ARVI. The medicinal product is prescribed in a dose of 500 mg for therapeutic purposes to adults and children over 12 years 3 times a day. The recommended dose of the medicinal product for children aged 6-12 years is 125 mg 2-3 times a day. The duration of treatment is 7 days. It should be noted that higher efficacy of the medicinal product is observed when therapy starts earlier.

The recommended dose of the medicinal product for adults and children over 16 years for prevention is 250 mg/day for 3-5 days, subsequently 250 mg once every 2-3 days for 2-3 weeks. Children aged 6-12 years should take 125 mg every other day for 2-3 weeks in order to prevent ARVI, and children aged 12-16 years – 250 mg every other day for 2-3 weeks.


Back to the News